GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The FDA has approved Bristol Myers Squibb’s (BMS) Opvido Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous (SC) administration in most adult solid tumor indications previously approved for ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Opdivo Qvantig combines nivolumab, a programmed death receptor ... executive vice president and chief commercialization officer for Bristol Myers Squibb. “With this new option, we look forward ...

Bristol Myers Squibb’s Opdivo (nivolumab), Palbociclib, sold under the brand name Ibrance by Pfizer, Xarelto (Rivaroxaban) by Bayer and J&J, Trulicity by Eli Lilly, Pfizer’s Prevnar 13 ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a paper published in the ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...